These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 20091169

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
    Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C.
    Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ.
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4108-15. PubMed ID: 14519633
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
    Thomas AL, Trarbach T, Bartel C, Laurent D, Henry A, Poethig M, Wang J, Masson E, Steward W, Vanhoefer U, Wiedenmann B.
    Ann Oncol; 2007 Apr 15; 18(4):782-8. PubMed ID: 17218488
    [Abstract] [Full Text] [Related]

  • 12. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, Kawauchi Y, Nikkuni K, Shimizu T, Sato T, Yanagi M, Takahashi S, Yoshida H, Sugita M, Hayashi T.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):267-73. PubMed ID: 18379784
    [Abstract] [Full Text] [Related]

  • 13. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
    Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA.
    Clin Cancer Res; 2001 Jun 15; 7(6):1600-9. PubMed ID: 11410496
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.
    Clin Cancer Res; 1999 Feb 15; 5(2):275-9. PubMed ID: 10037175
    [Abstract] [Full Text] [Related]

  • 15. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 16. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
    Harries M, O'Donnell A, Scurr M, Reade S, Cole C, Judson I, Greystoke A, Twelves C, Kaye S.
    Br J Cancer; 2004 Nov 01; 91(9):1651-5. PubMed ID: 15494716
    [Abstract] [Full Text] [Related]

  • 17. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.
    Strahlenther Onkol; 2003 Oct 01; 179(10):673-81. PubMed ID: 14566475
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1999 Feb 01; 5(2):299-308. PubMed ID: 10037178
    [Abstract] [Full Text] [Related]

  • 20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.
    Gynecol Oncol; 2005 Jan 01; 96(1):168-72. PubMed ID: 15589596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.